| Theme |
Complication of Inflammatory Bowel Disease |
| Title |
Massive Intestinal Bleeding |
| Author |
Ken Takeuchi |
Department of Gastroenterology, Sakura Medical Center, Toho University |
| Author |
Akihiro Yamada |
Department of Gastroenterology, Sakura Medical Center, Toho University |
| Author |
Koji Sono |
Department of Gastroenterology, Sakura Medical Center, Toho University |
| Author |
Aisaku Osamura |
Department of Gastroenterology, Sakura Medical Center, Toho University |
| Author |
Hiroshi Aoki |
Department of Gastroenterology, Sakura Medical Center, Toho University |
| Author |
Kentaro Nakamura |
Department of Gastroenterology, Sakura Medical Center, Toho University |
| Author |
Yasutsugu Yoshimatsu |
Department of Gastroenterology, Sakura Medical Center, Toho University |
| Author |
Nobuo Takada |
Department of Gastroenterology, Sakura Medical Center, Toho University |
| Author |
Yasuo Suzuki |
Department of Gastroenterology, Sakura Medical Center, Toho University |
| [ Summary ] |
Massive intestinal bleeding remains an unusual but serious complication in connection with inflammatory bowel disease. However, difficulties in locating the bleeding site add to morbidity. Endoscopy should be performed first because this can be done at the same time as endoscopic hemostasis. CT angiography and CT enterography using multi-detector row CTs (MDCT) are more helpful in detecting the bleeding site than angiography or scintigrams when treating Crohnʼs disease. Infliximab may be an alternative therapy for Crohnʼs disease with severe intestinal bleeding and recurrent hemorrhaging. Surgical treatment is recommended for patients not stabilized by transfusion, and for patients requiring conservative approaches. |